Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) CFO Jamie Samath sold 188 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $566.94, for a total transaction of $106,584.72. Following the completion of the transaction, the chief financial officer now owns 7,162 shares in the company, valued at approximately $4,060,424.28. This represents a 2.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Jamie Samath also recently made the following trade(s):
- On Monday, February 10th, Jamie Samath sold 269 shares of Intuitive Surgical stock. The shares were sold at an average price of $590.00, for a total transaction of $158,710.00.
- On Wednesday, January 29th, Jamie Samath sold 94 shares of Intuitive Surgical stock. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34.
- On Tuesday, December 10th, Jamie Samath sold 270 shares of Intuitive Surgical stock. The shares were sold at an average price of $540.15, for a total transaction of $145,840.50.
Intuitive Surgical Price Performance
NASDAQ:ISRG opened at $566.98 on Tuesday. The stock has a market cap of $201.95 billion, a P/E ratio of 88.45, a PEG ratio of 5.85 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $364.17 and a one year high of $616.00. The company has a fifty day moving average price of $570.66 and a 200 day moving average price of $530.08.
Hedge Funds Weigh In On Intuitive Surgical
Analysts Set New Price Targets
Several analysts have commented on the stock. Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $475.00 to $575.00 in a research report on Monday, January 27th. JPMorgan Chase & Co. boosted their target price on shares of Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Piper Sandler reissued an “overweight” rating and issued a $670.00 target price (up from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. Finally, Bernstein Bank boosted their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $613.10.
Check Out Our Latest Analysis on Intuitive Surgical
About Intuitive Surgical
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Featured Articles
- Five stocks we like better than Intuitive Surgical
- How to trade penny stocks: A step-by-step guide
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- How to Plot Fibonacci Price Inflection Levels
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.